HANALL BIOPHARMA CO., LTD – Company Intelligence Brief

1. Business Overview

[TRANSLATION NOTE: Company name transliteration used]

Hanall Biopharma Co., Ltd is a South Korean biopharmaceutical company trading on the Korean Exchange (stock code: 009420) with a market capitalization of approximately KRW 2.52 trillion as of the filing date. The company operates in the pharmaceutical and biopharmaceutical sector. Based on the consolidated financial statements (52nd fiscal year ending December 31, 2024), the company maintains both domestic and international operations. Specific business segment details regarding therapeutic areas or product lines are not disclosed in the available financial data, requiring reference to the original Korean-language business description sections of the DART filing for granular segment information.

2. Financial Trend

Revenue grew 3.0% year-over-year to KRW 138.9 billion in FY2024 (from KRW 134.9 billion in FY2023), continuing a multi-year growth trajectory from KRW 110.0 billion in FY2022. However, profitability deteriorated sharply. Operating profit collapsed 90% to just KRW 230 million in FY2024 from KRW 2.2 billion in FY2023, representing an operating margin compression from 1.6% to 0.2%. The company swung to a net loss of KRW 1.8 billion in FY2024 versus a profit of KRW 3.5 billion in FY2023.

The balance sheet shows modest strengthening. Total assets declined to KRW 212.9 billion from KRW 239.7 billion, primarily due to a sharp reduction in current assets (down KRW 28.2 billion). Total debt decreased to KRW 44.5 billion from KRW 53.5 billion, with the debt-to-equity ratio improving to 26.5% from 28.7%. Retained earnings fell to KRW 26.5 billion from KRW 31.4 billion, reflecting the loss absorption. The company maintains reasonable liquidity despite the profitability challenges.

3. Ownership Structure

Specific ownership structure details—including controlling shareholder identity, shareholding percentages, and foreign ownership proportion—are not included in the extracted balance sheet and income statement data provided. This information would be found in separate sections of the DART filing dedicated to shareholder composition and stock ownership disclosure, which are not available in this dataset. [TRANSLATION NOTE: Full ownership disclosure would require accessing additional Korean-language filing sections]

4. Key Risks

Margin Erosion Risk: The 90% decline in operating profit despite revenue growth indicates severe cost pressure or pricing challenges. The operating margin fell to near-zero (0.2%), suggesting the company is barely covering operating expenses, with no cushion for adverse developments.

Profitability Sustainability: The swing from KRW 3.5 billion profit to KRW 1.8 billion loss within one year, despite revenue growth, raises concerns about business model sustainability and competitive positioning in a capital-intensive biopharmaceutical industry.

5. Investment Consideration

Hanall Biopharma presents a growth-versus-profitability paradox—revenue expansion masks alarming margin collapse and loss-making operations that warrant investigation into cost structure and pipeline economics before considering exposure.